New hope for ITP patients: Head-to-Head drug trial launches
NCT ID NCT07051915
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. About 220 adults who did not improve with first-line steroids will receive either Avatrombopag (a daily pill that boosts platelet production) or Rituximab (an infusion that targets immune cells). The goal is to see which approach better maintains safe platelet levels and improves quality of life over 28 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.